Ozagrel Sodium CAS 130952-46-4 for Anti-Inflammatory Treatment

Product Description:

Product Name: Ozagrel sodium CAS NO: 130952-46-4

Synonyms:

sodium,3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoate;

4-(1h-imidazol-1-ylmethyl)cinnamic acid sodium salt;

Sodium 3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylate;

Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.00%

Boiling Point: 468℃ at 760 mmHg

Flash Point: 236.8℃

Safety Information:

HS Code: 2933290090

Ozagrel(OKY-046) sodium salt is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.Target: Thromboxane A2 SynthaseOzagrel was selected as the best compound of highly selective inhibitors of TXA2 synthase. The inhibition of TXA2 synthase by ozagrel was more effective on human and rabbit enzymes than those of other species. Ozagrel increased 6-keto-PGF1 alpha, one of stable metabolites of PGI2, in various isolated cells and tissues perhaps via accumulated PG endoperoxides resulted by the inhibition of TXA2 synthase. Ozagrel was estimated to be a reversible mixed-type inhibitor of diphenolase activity with the constants (K (S1), K (S2), K (i1), and K (i2)) determined to be 2.21, 3.89, 0.454, and 0.799 mM, repectively. Infusion of OKY-046 significantly inhibited pulmonary thromboxane B2 delivery, attenuated the early increase in pulmonary vascular resistance, and blocked the increase in systemic vascular resistance. In addition, OKY-046 blunted and delayed the decrease in cardiac output and maintained end-systolic pressure-diameter relation, +dp/dt, and lung lymph flow at baseline values.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.